Parathar, Forsteo(teriparatide)
Bonsity, Forsteo, Forteo, Kauliv, Livogiva, Movymia, Parathar, Sondelbay, Teriparatide, Terrosa (teriparatide) is a protein pharmaceutical. Teriparatide was first approved as Parathar on 1987-12-23. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis and postmenopausal osteoporosis. The pharmaceutical is active against parathyroid hormone/parathyroid hormone-related peptide receptor. In addition, it is known to target parathyroid hormone 2 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Bonsity, Forteo, Teriparatide (discontinued: Forteo, Parathar)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bonsity | New Drug Application | 2025-06-01 |
| forteo | New Drug Application | 2025-06-03 |
| teriparatide | ANDA | 2025-07-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postmenopausal osteoporosis | EFO_0003854 | D015663 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Teriparatide, Forteo, Lilly | |||
| 7517334 | 2025-03-25 | DP | |
HCPCS
Code | Description |
|---|---|
| J3110 | Injection, teriparatide, 10 mcg |
Clinical
Clinical Trials
195 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 10 | 29 | 18 | 26 | 28 | 108 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | 5 | 5 | 10 | 16 | 7 | 42 |
| Metabolic bone diseases | D001851 | — | — | 1 | 7 | 2 | 4 | 3 | 17 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | 1 | 5 | 3 | 3 | 3 | 13 |
| Spinal fractures | D016103 | EFO_0003902 | S12 | — | — | 1 | 1 | 3 | 5 |
| Stress fractures | D015775 | — | M84.3 | — | — | 2 | 1 | 1 | 4 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 3 | — | 1 | — | 4 |
| Chronic kidney disease-mineral and bone disorder | D012080 | EFO_1001152 | N25.0 | — | — | 1 | 1 | 1 | 3 |
| Osteogenesis imperfecta | D010013 | — | Q78.0 | — | 1 | — | 2 | — | 3 |
| Wounds and injuries | D014947 | — | T14.8 | — | 2 | — | 1 | — | 3 |
Show 13 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypoparathyroidism | D007011 | — | E20 | 1 | 9 | 6 | — | 3 | 17 |
| Osteoporotic fractures | D058866 | — | — | — | 3 | 1 | — | 4 | 8 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 2 | 1 | 3 | — | — | 6 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | 2 | 1 | — | 2 | 5 |
| Hypocalcemia | D006996 | HP_0002901 | E83.51 | — | 3 | 1 | — | — | 4 |
| Parathyroid diseases | D010279 | — | E21.5 | — | 1 | 3 | — | — | 4 |
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | — | — | 1 | — | 1 | 2 |
| Anorexia | D000855 | — | R63.0 | — | 1 | 1 | — | — | 2 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | 1 | 1 | — | — | 2 |
| Femoral neck fractures | D005265 | EFO_1001792 | S72.00 | — | — | 2 | — | — | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bone diseases | D001847 | — | M89.9 | 1 | 2 | — | — | 1 | 4 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 2 | — | — | 1 | 3 |
| Musculoskeletal diseases | D009140 | — | — | 1 | 1 | — | — | — | 2 |
| Colles' fracture | D003100 | — | S52.53 | — | 2 | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 1 | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | 1 | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 1 | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 1 | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 1 | — | — | — | 1 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | 2 | — | — | — | 1 | 3 |
| Endocrine bone diseases | D001849 | — | — | 2 | — | — | — | — | 2 |
| Hypercalcemia | D006934 | HP_0003072 | E83.52 | 1 | — | — | — | — | 1 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | — | 1 | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 1 | 1 |
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | — | — | 1 | 1 |
| Bisphosphonate-associated osteonecrosis of the jaw | D059266 | — | — | — | — | — | — | 1 | 1 |
| Spontaneous fractures | D005598 | — | M84.4 | — | — | — | — | 1 | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
| Osteomalacia | D010018 | EFO_1002027 | M83 | — | — | — | — | 1 | 1 |
| Mortality | D009026 | EFO_0004352 | — | — | — | — | — | 1 | 1 |
| Drug therapy | D004358 | — | — | — | — | — | — | 1 | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Teriparatide |
| INN | teriparatide |
| Description | TERIPARATIDE |
| Classification | Protein |
| Drug class | peptides: parathyroid hormone related peptide |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 52232-67-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL525610 |
| ChEBI ID | — |
| PubChem CID | 16132393 |
| DrugBank | DB06285 |
| UNII ID | 10T9CSU89I (ChemIDplus, GSRS) |
Target
Agency Approved
PTH1R
PTH1R
Organism
Homo sapiens
Gene name
PTH1R
Gene synonyms
PTHR, PTHR1
NCBI Gene ID
Protein name
parathyroid hormone/parathyroid hormone-related peptide receptor
Protein synonyms
Parathyroid hormone 1 receptor, parathyroid hormone receptor 1, parathyroid hormone/parathyroid hormone-related protein receptor, PTH/PTHr receptor, PTH/PTHrP type I receptor, PTH1 receptor, seven transmembrane helix receptor
Uniprot ID
Mouse ortholog
Pth1r (19228)
parathyroid hormone/parathyroid hormone-related peptide receptor (Q80WU8)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Forteo – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Teriparatide – Ligand Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Teriparatide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,197 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
128,728 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use